Sponsors (2)
The bill trades a short-term extension of market exclusivity to encourage development of rare/COVID-related therapies against higher drug costs and increased public and private healthcare spending for the duration of the extension.
Manufacturers of covered orphan drugs will receive 180 additional days of market exclusivity, delaying generic and biosimilar competition and increasing near-term returns on those products.
Patients with rare or COVID-19–related conditions stand to benefit indirectly because extending exclusivity preserves incentives for developers to invest in and complete research on new rare-disease therapies.
Patients with chronic conditions and their insurers will face higher drug prices for an extra 180 days because generics and biosimilars are delayed, increasing out-of-pocket and insurance costs.
Hospitals and health systems will incur higher procurement costs and budget pressure while lower-cost alternatives are blocked for an additional 180 days.
Taxpayers and private payers may face increased federal and private healthcare spending because extended exclusivity raises overall drug spending during the exclusivity extension.
Based on analysis of 2 sections of legislative text.
Adds a 180‑day extension to specified FDA exclusivity and patent‑delay periods for qualifying orphan drugs affected by the COVID‑19 emergency.
Extends certain FDA exclusivity and patent-related approval-delay periods by 180 days for qualifying orphan drugs whose regulatory timelines were affected by the COVID‑19 emergency. The extension applies immediately on enactment to specified biologics, NDA/ANDA/505-related exclusivities, and 7‑year orphan exclusivity, but only for drugs that meet a narrow definition of “covered orphan drug.” The bill defines the COVID‑19 emergency period, limits the extension to exclusivities that have not already expired, and makes the change effective upon enactment without waiting for agency rulemaking.
Official title: To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.
Introduced February 25, 2026 by Josh S. Gottheimer · Last progress February 25, 2026